// App-Quantinova.ai

: PBI-4050, a Novel First-in-Class Antifibrotic Agent, Improves Pulmonary Hypertension and Fibrosis, as Well as Right Ventricular Hypertrophy and Fibrosis in Monocrotaline-Treated Rats

Researchers

Presenter

  • Q. Nguyen

Principal Investigators

  • J. C. Tardif

  • Y. Shi

  • E. Plante

  • E. Nguyen-Duong

  • B. Grouix

  • P. Laurin

  • L. Gagnon

  • J. Dupuis

Medical Centers

  • Institut de Rhumatologie, Montreal, QC, Canada

  • Prometic Biosciences Inc., Laval, QC, Canada.

Locations

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Cardiovascular (CVS)

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Monocrotaline

  • Sildenafil citrate

  • PBI4050

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

Phase

  • II/III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved